Ethical issues with testing and treatment for Krabbe disease
نویسندگان
چکیده
منابع مشابه
Ethical Issues in Genetic Testing
Since genetic testing techniques are available, they never stopped being improved over the years. Theses techniques bring a greatest knowledge of the human genome. Thus, geneticists are now capable of diagnosis of genetic conditions, identification of at-risk patients for cancer.... Although genetic testing has been a major revolution in the practice of medicine, it goes without saying that it ...
متن کاملRestorative Therapies for Parkinson’s Disease: Ethical Issues
Improved health care and the many therapies and surgery methods for all kinds of previously life-threatening diseases have helped to increase the average lifespan of the world population. As a consequence, the incidence of disease connected with old age, in particular degenerative diseases of the brain, has increased: the human body outlives the normally aging brain. One of these diseases is Pa...
متن کاملPanel on ethical issues in genetic testing.
DR. MICHAEL K1TA, UNUM Mutual: Good morning. Yesterday morning teed up some of the medical and scientific issues around genetic testing, and this morning we will have two panels on ethical issues and on legal issues around genetic testing. I’ll be introducing each speaker in succession. They will have some prepared remarks and then we will proceed to a panel discussion and some interactive line...
متن کاملEthical issues of predictive genetic testing for diabetes.
With the rising number of individuals affected with diabetes and the significant health care costs of treatment, the emphasis on prevention is key to controlling the health burden of this disease. Several genetic and genomic studies have identified genetic variants associated with increased risk to diabetes. As a result, commercial testing is available to predict an individual's genetic risk. A...
متن کاملEthical and value issues in insurance coverage for cancer treatment.
Many new cancer drugs provide only limited benefits, but at very great cost, for example, $200,000-$300,000 per quality-adjusted life year produced. By most standards of value or cost-effectiveness, this does not represent good value. I first review several of the causes of this value failure, including monopoly patents, prohibitions on Medicare's negotiating on drug prices, health insurance pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Developmental Medicine & Child Neurology
سال: 2019
ISSN: 0012-1622,1469-8749
DOI: 10.1111/dmcn.14258